Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Glancing Back, Looking Forward: Lasting Lessons for Years to Come

News Opinion Editor's Corner

Glancing Back, Looking Forward: Lasting Lessons for Years to Come

December 27, 2021

Home School: Clinical Trials Went Virtual in COVID-19—Are They Here to Stay?

News Features

Home School: Clinical Trials Went Virtual in COVID-19—Are They Here to Stay?

December 09, 2021

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

News Daily News

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

December 03, 2021

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

COVID-19: TCTMD’s Dispatch for November Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 3

November 15, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

News Daily News

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

October 01, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

COVID-19: TCTMD’s Daily Dispatch for September Week 2

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September Week 2

September 08, 2021

TCTMD’s Top 10 Most Popular Stories for August 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2021

September 03, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 2

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 2

August 08, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.